| Literature DB >> 31011359 |
Yun-Fei Xie1,2, Wu-Wen Feng1, Mei-Chen Liu1, Jun Xie1, Lei Yu1, Xiao-Hong Gong1, Yun-Xia Li1, Cheng Peng1.
Abstract
Combination of Aconiti Lateralis Radix Praeparata (FZ) and Paeoniae Radix Alba (BS) shows a significant effect in rheumatoid arthritis (RA). This study aimed to investigate the efficacy enhancing and toxicity reducing mechanism of combination of them in adjuvant-induced arthritis (AIA) rats by metabolomics. Rats were randomly divided into seven groups, including A (healthy control), B (model control), C1 (therapy group), C2 (efficacy enhancing group), D1 (toxicity group), and D2 (toxicity reducing group), and dexamethasone group was used as positive control. The plasma biochemical indexes showed that therapeutic dose of lipid-soluble alkaloids of FZ could significantly inhibit the concentrations of IL-1β, TNF-α, and IFN-γ in AIA rats, and combination with total glucosides of peony could further reduce the concentration of IL-1β. Then, UPLC-LTQ/Orbitrap MS with untargeted metabolomics was performed to identify the possible metabolites and pathways. Through multivariate data analysis of therapeutic dose groups (A vs. B vs. C1 vs. C2) and multivariate data analysis of toxic dose groups (A vs. B vs. D1 vs. D2), 10 and 7 biomarkers were identified based on biomarker analysis, respectively. After inducing AIA model, the plasma contents of spermidine, vanillylmandelic acid, catechol, and linoleate were increased significantly, and the contents of citric acid, L-tyrosine, L-phenylalanine, leucine, L-tryptophan, and uridine 5'-monophosphate (UMP) were decreased significantly. High dose of lipid-soluble alkaloids of FZ could increase the plasma contents of L-lysine, L-arginine, and deoxycholic acid, while the plasma contents of UMP, carnitine, N-formylanthranilic acid, and adenosine were decreased significantly. The pathway analysis indicated that therapeutic dose of lipid-soluble alkaloids of FZ could regulate energy and amino acid metabolic disorders in AIA rats. However, toxic dose could cause bile acid, fat, amino acid, and energy metabolic disorders. And combination with total glucosides of peony could enhance the therapeutic effects and attenuate the toxicity induced by lipid-soluble alkaloids of FZ.Entities:
Year: 2019 PMID: 31011359 PMCID: PMC6442482 DOI: 10.1155/2019/9864841
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1(a) The body weight of rats in each group after immunization, weighed every 3 days. (b) The change of paw volumes of rats in each group after immunization, measured every 4 days. (c) The clinical arthritis scores in each group after immunization, evaluated every 4 days. Healthy control group (A). AIA model group (B). Therapy group (C1). Efficacy enhancing combination group (C2). Toxicity group (D1). Toxicity reducing combination group (D2). Dexamethasone group (DG).
Effect of combination of FZ and BS on IL-1β, TNF-α, and IFN-.
| Group | IL-1 | TNF- | IFN- |
|---|---|---|---|
| A group | 217.39±61.22 | 135.20±17.86 | 154.23±43.04 |
| B group | 731.26±156.34### | 164.24±18.82# | 506.03±191.55## |
| C1 group | 547.62±172.16 | 145.05±17.85 | 198.84±54.15 |
| C2 group | 262.96±191.44 | 143.20±18.85 | 182.98±88.86 |
| D1 group | 535.62±154.12 | 146.37±24.72 | 209.58±69.74 |
| D2 group | 375.62±143.54 | 148.54±26.84 | 186.47±71.19 |
| Dexamethasone group | 239.42±102.37 | 140.30±19.10 | 185.88±67.94 |
Significant differences were based on independent sample t-test.
# P < 0.05, compared with control group; ##P < 0.01, compared with control group; ###P < 0.001, compared with control group.
P < 0.05, compared with model group; P < 0.01, compared with model group; P < 0.001, compared with model group
Healthy control group (A). AIA model group (B). Therapy group (C1). Efficacy enhancing combination group (C2). Toxicity group (D1). Toxicity reducing combination group (D2). Dexamethasone group (DG).
Figure 2UPLC-LTQ/Orbitrap MS TIC chromatograms of the plasma samples from six groups in positive and negative modes. 1. Uridine 5'-monophosphate (UMP); 2. Spermidine; 3. L-Lysine; 4. Carnitine; 5. L-Arginine; 6. L-Tyrosine; 7. N-Formylanthranilic acid; 8. L-Phenylalanine; 9. Leucine; 10. L-Tryptophan; 11. L-Isoleucine; 12. Vanillylmandelic acid; 13. Catechol; 14. Linoleate; 15. Citric acid; 16. Adenosine; 17. Deoxycholic acid. Healthy control group (A). AIA model group (B). Therapy group (C1). Efficacy enhancing combination group (C2). Toxicity group (D1). Toxicity reducing combination group (D2).
Figure 3The PLS-DA score plot of therapeutic dose groups (A vs. B vs. C1 vs. C2) in ESI+ and ESI−. Healthy control group (A). AIA model group (B). Therapy group (C1). Efficacy enhancing combination group (C2).
Figure 4The PLS-DA score plot of toxic dose groups (A vs. B vs. D1 vs. D2) in ESI+ and ESI−. Healthy control group (A). AIA model group (B). Toxicity group (D1). Toxicity reducing combination group (D2).
Figure 5100-permutation test of PLS-DA model of therapeutic dose groups (A vs. B vs. C1 vs. C2) in ESI+ and ESI−.
Figure 6100-permutation test of PLS-DA model of toxic dose groups (A vs. B vs. D1 vs. D2) in ESI+ and ESI−.
Figure 7The PLS-DA S-plot in ESI+ and ESI−.
List of the identification of potential biomarkers among groups.
| No. | Biomarker identification | m/z | ppm | ESI mode | Rt/min | Formula | B vs. A | C1 vs. B | C2 vs. B | Pathway |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Spermidine | 146.16467 | 6.64 | + | 0.91 | C7H19N3 | ↑## | ↓ | ↑ | Arginine and proline metabolism |
| 2 | Citric acid | 191.01813 | 9.03 | − | 1.52 | C6H8O7 | ↓# | ↑ | ↑ | Citrate cycle |
| 3 | L-Tyrosine | 182.08048 | 4.64 | + | 1.65 | C9H11NO3 | ↓# | ↓ | ↑ | Phenylalanine metabolism |
| 4 | L-Phenylalanine | 166.08602 | 1.49 | + | 3.15 | C9H11NO2 | ↓# | ↑ | ↑ | Phenylalanine metabolism |
| 5 | Leucine | 132.10130 | 2.60 | + | 3.23 | C6H13NO2 | ↓# | ↑ | ↑ | Valine, leucine and isoleucine biosynthesis |
| 6 | L-Tryptophan | 205.09676 | 1.79 | + | 3.92 | C11H12N2O2 | ↓# | ↑ | ↑ | Tryptophan metabolism |
| 7 | L-Isoleucine | 132.10129 | 2.41 | + | 4.63 | C6H13NO2 | ↓ | ↓ | ↑ | Valine, leucine and isoleucine biosynthesis |
| 8 | Vanillylmandelic acid | 199.16870 | 12.35 | + | 11.80 | C9H10O5 | ↑### | ↑ | ↓ | Tyrosine metabolism |
| 9 | Catechol | 111.01985 | 9.46 | + | 13.07 | C6H6O2 | ↑# | ↓ | ↓ | Tyrosine metabolism |
| 10 | Linoleate | 281.24722 | 5.86 | + | 14.84 | C18H32O2 | ↑## | ↓ | ↓ | Linoleic acid metabolism |
↑: the compound was upregulated; ↓: the compound was downregulated.
# P < 0.05, compared with control group; ##P < 0.01, compared with control group; ###P < 0.001, compared with control group.
P < 0.05, compared with model group; P < 0.01, compared with model group; P < 0.001, compared with model group.
List of the identification of potential biomarkers among groups.
| No. | Biomarker identification | m/z | ppm | ESI mode | Rt/min | Formula | B vs. A | D1 vs.B | D2 vs. D1 | Pathway |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | UMP | 324.21578 | 7.38 | + | 0.78 | C9H13N2O9P | ↓# | ↓ | ↑ | Pyrimidine metabolism |
| 2 | L-Lysine | 147.11222 | 0.07 | + | 0.98 | C6H14N2O2 | ↑ | ↑ | ↓△ | Lysine biosynthesis |
| 3 | Carnitine | 162.11193 | 6.44 | + | 1.13 | C7H15NO3 | ↓ | ↓ | ↑△ | Bile secretion |
| 4 | L-Arginine | 175.11846 | 1.68 | + | 1.14 | C6H14N4O2 | ↑ | ↑ | ↓△ | Arginine and proline metabolism |
| 5 | N-Formylanthranilic acid | 166.04688 | 18.18 | + | 2.83 | C8H7NO3 | ↓ | ↓ | ↓ | Tryptophan metabolism |
| 6 | Adenosine | 265.94792 | 7.65 | − | 9.60 | C10H13N5O4 | ↓ | ↓ | ↑ | Purine metabolism |
| 7 | Deoxycholic acid | 391.28221 | 0.28 | − | 12.10 | C24H40O4 | ↑ | ↑ | ↑ | Bile secretion |
↑: the compound was upregulated; ↓: the compound was downregulated.
# P < 0.05, compared with control group; ##P < 0.01, compared with control group; ###P < 0.001, compared with control group.
P < 0.05, compared with model group; P < 0.01, compared with model group; P < 0.001, compared with model group.
△ P < 0.05, compared with D1 group; △△P < 0.01, compared with D1 group; △△△P < 0.001, compared with D1 group.
Figure 8The metabolic pathway networks of potential biomarkers in response to therapeutic and toxic mechanism of combination of FZ and BS in AIA rats. The red marked metabolites were associated with the therapeutic mechanism. The blue marked metabolites were associated with the toxic mechanism.